BioCentury | Aug 23, 2019
Distillery Therapeutics

KRAS inhibitor combinations for improved therapeutic efficacy

...treat bladder cancer. Small molecule FGFR inhibitors Balversa erdafitinib from Otsuka Pharmaceutical Co. Ltd. and anlotinib...
BioCentury | Jan 5, 2019
Finance

Ready to launch

The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record year...
BioCentury | Oct 10, 2018
Politics & Policy

China adds insurance coverage for 17 cancer therapies

...is myelofibrosis drug Jakavi ruxolitinib from Incyte Corp. (NASDAQ:INCY) and Novartis AG (NYSE:NVS; SIX:NOVN). Sandi Wong anlotinib (AL3818...
BioCentury | Aug 17, 2018
Politics & Policy

China unveils cancer drugs for medical insurance access negotiation

...Erbitux cetuximab from Eli Lilly and Co. (NYSE:LLY) and Merck KGaA for CRC; Focus V anlotinib...
BioCentury | Jun 30, 2018
Finance

Hidden in the rough

...Ltd. / Advenchen Laboratories LLC / Sino Biopharmaceutical Ltd. (HKSE:1177) China SDA approves Focus V anlotinib...
BioCentury | May 18, 2018
Clinical News

CTTQ's tyrosine kinase inhibitor gets Chinese approval for NSCLC

...The State Drug Administration (formerly CFDA) approved Focus V anlotinib from Chia Tai Tianqing Pharmaceutical Group...
...Ltd. (Nanjing, China) to treat advanced non-small cell lung cancer. CTTQ has Chinese rights to anlotinib...
...Ltd., Nanjing, China Advenchen Laboratories LLC, Moorpark, Calif. Product: Focus V anlotinib Business: Cancer Chris Lieu Anlotinib (AL3818) Advenchen...
BioCentury | May 11, 2018
Company News

CTTQ's tyrosine kinase inhibitor gets Chinese approval for NSCLC

...The State Drug Administration (formerly CFDA) approved Focus V anlotinib from Chia Tai Tianqing Pharmaceutical Group...
...Ltd. (Nanjing, China) to treat advanced non-small cell lung cancer. CTTQ has Chinese rights to anlotinib...
...BioCentury, June 6, 2016) . CTTQ is a subsidiary of Sino Biopharmaceutical Ltd. (HKSE:1177). Chris Lieu Anlotinib (AL3818) Advenchen...
BioCentury | Jul 21, 2017
Clinical News

Chia Tai Tianqing reports Phase III data for anlotinib in NSCLC

...after ≥2 lines of therapy showing that third-line treatment with once-daily 12 mg oral anlotinib (AL3818...
...primary endpoint of improving median overall survival (OS) vs. placebo (9.63 vs. 6.3 months, p=0.0018). Anlotinib...
...Moorpark, Calif. Chia Tai Tianqing Pharmaceutical Group Co. Ltd. , Nanjing, China Product: Anlotinib (AL3818...
BioCentury | Jun 6, 2016
Clinical News

Anlotinib: Phase II data

...patients with STS in an open-label, Chinese Phase II trial showed that once-daily 12 mg anlotinib...
...11.45%, median progression-free survival (PFS) of 5.63 months and a 12-week PFS rate of 57.23%. Anlotinib...
...Oncology meeting in Chicago. Chia Tai Tianqing Pharmaceutical Group Co. Ltd. , Nanjing, China Product: Anlotinib...
Items per page:
1 - 9 of 9